|
1
|
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
|
Hepatology
|
2006
|
10.18
|
|
2
|
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.
|
AIDS
|
2005
|
3.07
|
|
3
|
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.
|
AIDS
|
2007
|
1.78
|
|
4
|
Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults.
|
J Acquir Immune Defic Syndr
|
2005
|
1.47
|
|
5
|
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
|
AIDS Res Hum Retroviruses
|
2005
|
1.37
|
|
6
|
Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl.
|
Emerg Infect Dis
|
2009
|
1.04
|
|
7
|
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
|
AIDS
|
2004
|
1.01
|
|
8
|
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
J Acquir Immune Defic Syndr
|
2008
|
0.97
|
|
9
|
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.
|
J Clin Lipidol
|
2008
|
0.94
|
|
10
|
Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis.
|
Retina
|
2006
|
0.88
|
|
11
|
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
|
J Acquir Immune Defic Syndr
|
2002
|
0.86
|
|
12
|
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.
|
AIDS Res Ther
|
2011
|
0.85
|
|
13
|
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
|
AIDS
|
2007
|
0.85
|
|
14
|
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
|
J Infect Dis
|
2003
|
0.84
|
|
15
|
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.
|
HIV Clin Trials
|
2012
|
0.81
|
|
16
|
Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection.
|
Cardiovasc Toxicol
|
2004
|
0.80
|
|
17
|
Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach.
|
Retina
|
2004
|
0.80
|
|
18
|
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
|
J Clin Virol
|
2006
|
0.79
|
|
19
|
Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
|
ACP J Club
|
2005
|
0.78
|
|
20
|
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
|
AIDS
|
2013
|
0.78
|
|
21
|
Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.
|
AIDS Res Hum Retroviruses
|
2013
|
0.77
|
|
22
|
Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'.
|
AIDS
|
2006
|
0.75
|